Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Irish HTA body a step nearer:

This article was originally published in Clinica

Executive Summary

Ireland's ministry of health and children has announced the panel of experts responsible for establishing the national health technology assessment body. Pending its enactment, the Health Information and Quality Authority will be central to delivering "high-quality services that are based on evidence-supported best practice". The 12-member board of the interim body includes: Dolores Quinn, account manager of Abbott Laboratories' Diagnostic Division (see page 22); and Dr Ian Callanan, a specialist in orthopaedic surgery and healthcare management, and president of the Irish Society for Quality and Safety in Healthcare. It will be chaired by Mr Pat McGrath, managing director of the Project Management Group and said to have "extensive experience in dealing with regulatory authorities".

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT054173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel